Related Experiment Video

Updated: Jun 16, 2025

Methyl-binding DNA capture Sequencing for Patient Tissues
08:40

Methyl-binding DNA capture Sequencing for Patient Tissues

Published on: October 31, 2016

8.6K

Methylation modification of non-histone proteins in breast cancer: An emerging targeted therapeutic strategy

Mingyao Huang1, Zirong Jiang2, Yadan Xu3

  • 1Department of Breast Surgery, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou 350011, China.

Pharmacological Research
|August 18, 2024
PubMed

Insights

Non-histone methylation plays a key role in breast cancer development and progression. Targeting enzymes like protein arginine methyltransferases (PRMTs) and lysine methyltransferases (KMTs) offers new therapeutic strategies for breast cancer treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Breast cancer is a leading cause of cancer deaths globally, particularly among women.
  • Non-histone methylation regulates critical cellular processes involved in cancer, including oncogenesis and immune response.
  • Aberrant methylation patterns are increasingly recognized as significant drivers in breast cancer progression.

Purpose of the Study:

  • To review the enzymes involved in non-histone methylation, such as protein arginine methyltransferases (PRMTs) and lysine methyltransferases (KMTs).
  • To explore the molecular mechanisms and functional roles of non-histone methylation in breast cancer.
  • To discuss the therapeutic potential of targeting these methylation pathways for improved breast cancer treatment and overcoming drug resistance.

Main Methods:

  • Literature review of recent studies on non-histone methylation in breast cancer.
  • Analysis of the roles of specific methyltransferases (PRMTs, KMTs) and demethylases.
  • Examination of the impact of methylation on protein function and cancer-related pathways.

Main Results:

  • Non-histone methylation significantly influences protein activity, localization, and stability, affecting oncogenesis, tumor growth, invasion, and immune evasion.
  • Specific methyltransferases and demethylases are implicated in modulating breast cancer progression.
  • Dysregulated methylation pathways are linked to therapeutic resistance in breast cancer.

Conclusions:

  • Non-histone methylation is a critical regulatory mechanism in breast cancer.
  • Targeting methyltransferases and demethylases presents promising therapeutic avenues for breast cancer.
  • Further research into these pathways could lead to novel strategies to enhance treatment efficacy and overcome drug resistance.
Keywords:
Breast cancersCancer therapyEpigenetic modificationNon-histone methylationPost-translational modification

More Related Videos

Continuous Fluorescence-Based Endonuclease-Coupled DNA Methylation Assay to Screen for DNA Methyltransferase Inhibitors06:07

Continuous Fluorescence-Based Endonuclease-Coupled DNA Methylation Assay to Screen for DNA Methyltransferase Inhibitors

Published on: August 5, 2022

2.6K
Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

16.7K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Epigenetic Regulation01:37

Epigenetic Regulation

Epigenetic changes alter the physical structure of the DNA without changing the genetic sequence and often regulate whether genes are turned on or off. This regulation ensures that each cell produces only proteins necessary for its function. For example, proteins that promote bone growth are not produced in muscle cells. Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
X-chromosome...
3.0K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
Phase II Reactions: Methylation Reactions01:17

Phase II Reactions: Methylation Reactions

Methylation is a phase II biotransformation process involving the attachment of a methyl group to a substrate. Enzymes known as methyltransferases orchestrate this reaction.
The mechanism of methylation unfolds in two stages. The first stage sees a methyltransferase enzyme facilitating the transfer of a methyl group from S-adenosylmethionine (SAM) to the substrate, forming S-adenosylhomocysteine (SAH). The second stage involves further metabolism of SAH into homocysteine, which can be recycled...
164
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
21.2K